IMGN [NASD]
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own0.30% Shs Outstand254.41M Perf Week-3.61%
Market Cap915.30M Forward P/E- EPS next Y-0.52 Insider Trans0.00% Shs Float219.84M Perf Month-4.31%
Income-222.90M PEG- EPS next Q-0.25 Inst Own93.10% Short Float / Ratio10.37% / 6.43 Perf Quarter-20.00%
Sales108.80M P/S8.41 EPS this Y-30.10% Inst Trans1.93% Short Interest22.80M Perf Half Y-23.66%
Book/sh0.61 P/B6.44 EPS next Y2.10% ROA-55.30% Target Price12.33 Perf Year-23.95%
Cash/sh1.18 P/C3.33 EPS next 5Y- ROE-100.20% 52W Range3.10 - 6.63 Perf YTD-19.35%
Dividend- P/FCF- EPS past 5Y2.10% ROI-142.60% 52W High-39.67% Beta0.94
Dividend %- Quick Ratio2.50 Sales past 5Y-1.20% Gross Margin99.80% 52W Low29.24% ATR0.23
Employees277 Current Ratio2.50 Sales Q/Q47.10% Oper. Margin- RSI (14)45.72 Volatility4.45% 6.42%
OptionableYes Debt/Eq0.00 EPS Q/Q-37.90% Profit Margin- Rel Volume0.48 Prev Close3.93
ShortableYes LT Debt/Eq0.00 EarningsMar 01 BMO Payout- Avg Volume3.55M Price4.00
Recom1.90 SMA20-0.78% SMA50-7.53% SMA200-18.91% Volume487,986 Change1.78%
Nov-21-22Initiated Truist Buy $10
Sep-09-22Initiated Barclays Overweight $8
Mar-21-22Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $6
Feb-11-22Initiated BMO Capital Markets Outperform $18
Dec-01-21Upgrade Jefferies Hold → Buy $7 → $12
Oct-26-20Resumed H.C. Wainwright Buy $11
Oct-02-20Upgrade Guggenheim Neutral → Buy $14
Sep-29-20Resumed JP Morgan Neutral
Dec-17-19Reiterated H.C. Wainwright Buy $5 → $9
Aug-13-19Reiterated H.C. Wainwright Buy $4 → $5
Show Previous Ratings
Mar-03-23 11:11AM
Mar-01-23 10:35PM
04:30PM
01:27PM
07:45AM
06:30AM Loading…
06:30AM
06:25AM
Feb-22-23 04:30PM
10:00AM
Feb-21-23 01:23AM
Feb-16-23 05:34AM
Feb-15-23 04:01PM
Feb-01-23 04:30PM
Jan-04-23 04:30PM
06:30AM
04:47AM Loading…
04:47AM
Jan-03-23 07:45AM
Dec-30-22 09:30AM
Dec-28-22 04:30PM
12:56PM
Dec-27-22 04:30PM
Dec-15-22 06:10AM
Dec-12-22 10:55AM
Dec-10-22 10:30AM
Dec-09-22 06:30AM
Dec-05-22 05:30AM
Dec-01-22 04:30PM
Nov-21-22 06:30AM
Nov-17-22 06:45AM
05:52AM
02:21PM Loading…
Nov-16-22 02:21PM
Nov-15-22 12:56PM
06:16AM
Nov-14-22 04:30PM
Nov-09-22 07:53AM
Nov-07-22 02:07PM
Nov-04-22 07:45AM
06:30AM
Nov-03-22 08:48AM
Nov-01-22 04:30PM
10:01AM
06:30AM
Oct-28-22 10:00AM
08:40AM
Oct-20-22 04:01PM
Oct-03-22 04:30PM
Sep-29-22 08:00AM
Sep-14-22 04:30PM
Sep-11-22 06:00AM
Sep-02-22 11:31AM
Sep-01-22 04:30PM
12:42PM
11:31AM
Aug-31-22 06:30AM
Aug-01-22 04:30PM
11:13AM
Jul-30-22 11:30AM
Jul-29-22 07:45AM
06:30AM
Jul-14-22 04:01PM
Jul-01-22 04:30PM
Jun-14-22 10:02AM
Jun-13-22 01:28PM
06:30AM
Jun-01-22 04:30PM
May-26-22 05:00PM
May-25-22 04:30PM
May-24-22 09:39AM
May-23-22 07:59AM
06:30AM
May-10-22 04:30PM
May-06-22 01:30PM
07:45AM
06:30AM
May-03-22 08:55AM
May-02-22 04:30PM
Apr-28-22 11:18AM
Apr-21-22 04:01PM
Apr-01-22 04:30PM
11:23AM
Mar-31-22 04:30PM
Mar-30-22 11:51AM
Mar-29-22 06:30AM
Mar-21-22 03:07PM
03:00PM
08:26AM
Mar-19-22 07:15PM
Mar-10-22 06:30AM
Mar-01-22 04:30PM
Feb-28-22 10:20AM
Feb-27-22 09:16PM
07:48AM
Feb-25-22 07:45AM
06:30AM
Feb-23-22 04:30PM
Feb-16-22 10:58AM
10:46AM
Feb-15-22 11:19AM
06:40AM
06:30AM
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harrington-Smith KristenSVP & CHIEF COMMERCIAL OFFICERNov 15Option Exercise0.0025,000025,000Nov 18 05:31 PM